Twist Bioscience Corp
For the period ended Jun 30, 2024. Filed Aug 2, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 2, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
| Three months endedJune 30, | Nine months endedJune 30, | |||
|---|---|---|---|---|
| (In thousands, except per share data) | 2024 | 2023 | 2024 | 2023 |
| Revenues [1] | $81,464 | $63,740 | $228,264 | $178,163 |
| Operating expenses: | ||||
| Cost of revenues | $46,193 | $41,845 | $133,148 | $112,956 |
| Research and development | 22,469 | 24,528 | 69,718 | 83,148 |
| Selling, general and administrative | 56,794 | 46,057 | 165,256 | 142,347 |
| Restructuring and other costs | — | 9,052 | — | 9,052 |
| Impairment of long-lived assets | 44,930 | 3,620 | 44,930 | 3,620 |
| Change in fair value of contingent considerations and holdbacks | — | (581) | — | (5,913) |
| Total operating expenses | $170,386 | $124,521 | $413,052 | $345,210 |
| Loss from operations | $(88,922) | $(60,781) | $(184,788) | $(167,047) |
| Interest income | 3,663 | 3,968 | 11,724 | 10,472 |
| Interest expense | — | (1) | — | (4) |
| Other income (expense), net | (121) | 41 | (351) | (422) |
| Loss before income taxes | $(85,380) | $(56,773) | $(173,415) | $(157,001) |
| Income tax provision | (191) | (622) | (656) | (1,374) |
| Net loss attributable to common stockholders | $(85,571) | $(57,395) | $(174,071) | $(158,375) |
| Other comprehensive loss: | ||||
| Change in unrealized gain (loss) on investments | (21) | (208) | 56 | 1,308 |
| Foreign currency translation adjustment | (54) | (538) | (35) | (100) |
| Comprehensive loss | (85,646) | (58,141) | (174,050) | (157,167) |
| Net loss per share attributable to common stockholders—basic and diluted | $(1.47) | $(1.01) | $(3.01) | $(2.79) |
| Weighted average shares used in computing net loss per share attributable to common stockholders—basic and diluted | 58,145 | 57,041 | 57,806 | 56,753 |
[1]During the three and nine months ended June 30, 2024, the Company generated revenues from related parties totaling of $4.1 million and $9.7 million, respectively. During the three and nine months ended June 30, 2023, the Company generated revenues from related parties totaling $0.9 million and $3.6 million, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.